Literature DB >> 18952395

Adherence to nebulised antibiotics in cystic fibrosis.

Gary Latchford1, Alistair Duff, Joanne Quinn, Steve Conway, Mark Conner.   

Abstract

OBJECTIVE: To examine the adherence of patients with cystic fibrosis to nebulised antibiotics.
METHODS: A longitudinal design with adherence data collected over 12 weeks. 38 patients (mean age 24.6 years, S.D. 5.3) were recruited from an adult cystic fibrosis (CF) clinic. Adherence was electronically monitored using a Prodose adaptive aerosol delivery (AAD) device.
RESULTS: Three indices of adherence were calculated: mean percentage of times the nebuliser was used as prescribed was 50.0% (S.D.=39.7, range 1.1, 155.6); mean percentage of days fully adhered was 31.6% (S.D.=29.4, range 0, 97.2); mean percentage of days nebuliser used at least once was 57.1% (S.D.=34.2, range 3.3, 100).
CONCLUSION: Rates of adherence were generally low. Adherence was not associated with any variables apart from age. There were wide variations between individuals, and differences in rates of adherence depending on how this was defined, with potentially important health consequences for the patients. PRACTICE IMPLICATIONS: Technology that improves medication administration may still be associated with low rates of adherence. Health professionals need to be mindful of the pattern of non-adherence for each individual, and factors which may be influencing this.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952395     DOI: 10.1016/j.pec.2008.08.027

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  13 in total

1.  Parent-to-Child Transition in Managing Cystic Fibrosis: A Research Synthesis.

Authors:  Jennifer Leeman; Margarete Sandelowski; Nancy L Havill; Kathleen Knafl
Journal:  J Fam Theory Rev       Date:  2015-06

2.  Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.

Authors:  Ateesha Farah Mohamed; F Reed Johnson; Maria-Magdalena Balp; Frederico Calado
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

3.  Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives.

Authors:  Gregory S Sawicki; Karen S Heller; Nathan Demars; Walter M Robinson
Journal:  Pediatr Pulmonol       Date:  2014-03-10

Review 4.  The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.

Authors:  John Denyer; Tony Dyche
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Factors affecting nebulised medicine adherence in adult patients with cystic fibrosis: a qualitative study.

Authors:  Alice Hogan; Mary-Ann Bonney; Jo-Anne Brien; Rita Karamy; Parisa Aslani
Journal:  Int J Clin Pharm       Date:  2014-11-29

6.  Motivational interviewing for adherence problems in cystic fibrosis; evaluation of training healthcare professionals.

Authors:  Alistair James Aitken Duff; Gary Joseph Latchford
Journal:  J Clin Med Res       Date:  2013-10-12

7.  Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.

Authors:  Remi Flicoteaux; Camelia Protopopescu; Annick Tibi; Thierry Blanchon; Sylvie Van Der Werf; Xavier Duval; Anne Mosnier; Cécile Charlois-Ou; Bruno Lina; Catherine Leport; Sylvie Chevret
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

8.  Patient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis.

Authors:  Ann Hsu-An Lin; Jennifer G Kendrick; Pearce G Wilcox; Bradley S Quon
Journal:  Patient Prefer Adherence       Date:  2017-03-30       Impact factor: 2.711

Review 9.  Inhaled therapy in cystic fibrosis: agents, devices and regimens.

Authors:  Penny Agent; Helen Parrott
Journal:  Breathe (Sheff)       Date:  2015-06

Review 10.  Update on key emerging challenges in cystic fibrosis.

Authors:  Mark T Jennings; Kristin A Riekert; Michael P Boyle
Journal:  Med Princ Pract       Date:  2014-01-10       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.